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ABSTRACT.
Background.
Eyelid warming is an important treatment for meibomian gland dysfunction (MGD). Specialized chambered devices, using
warm moist air have been developed.
Purpose.
To critically evaluate the literature on the safety and efficacy of chambered warm moist air devices in MGD treatment and
pinpoint areas of future research.
Methods.
PubMed and Embase were searched on 06 June 2021. The search term was ‘(warm OR heat OR steam OR goggle OR
spectacle OR moist air) AND (meibomian OR MGD OR blepharitis OR eyelid OR dry eye OR DED)’. All relevant
articles with available English full text were included.
Results.
Eighteen articles assessing the application of chambered warm moist air eyelid warming devices were identified. In single-
application studies, steam-based eyelid warming increased the eyelid temperature and improved symptoms, lipid layer
thickness, and tear film breakup time (TBUT). In treatment studies, the steam-based devices improved TBUT and
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symptom scores. However, in the only randomized controlled trial (RCT) comparing chambered steam-based heat to hot
towel treatment, there was no difference between groups for the primary outcome measure; the proportion of subjects noting
symptom improvement after 4 weeks.
Conclusion.
Currently available chambered warm moist air eyelid warming devices are safe and effective at raising eyelid temperature
to therapeutic levels and improving signs and symptoms of dry eye. However, it is not clear if they provide a greater benefit
than other eyelid warming therapies. Further well-conducted RCTs comparing moist and dry heat devices should be
conducted on patients across the range of DED severities and subtype spectrum.
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Introduction
The tear film is a complex and dynamic
protective layer covering the cornea
and conjunctiva. The tear film is made
up of water, proteins, mucins, vitamins,
and fatty acids that all have different
roles in maintaining a healthy ocular
surface (Willcox et al. 2017). The tear
film presents a physical and immuno-
logical barrier to the external environ-
ment and protects the ocular surface
against dehydration and irritation
(Akpek & Gottsch 2003; Barabino
et al. 2012). Maintaining tear film
homeostasis is essential for good visual
quality and ocular surface health. Dry
eye disease (DED) represents a loss of
tear film homeostasis, resulting in
symptoms such as dryness, grittiness,
and foreign body sensation, as well as
damage and inflammation of the ocular
surface (Craig et al. 2017). Dry eye
disease (DED) causes a substantial
reduction in quality of life (Schiffman
et al. 2003; Miljanovic et al. 2007;
Uchino & Schaumberg 2013), affecting
social life (Uchino & Schaumberg
2013), work productivity (Uchino &
Schaumberg 2013; Uchino et al. 2014;
McDonald et al. 2016), sleep quality
(Magno et al. 2021), and health care
costs (Yu et al. 2011; McDonald et al.
2016). Dry eye disease (DED) is a
highly prevalent condition, affecting a
large proportion of the world’s popu-
lation (Stapleton et al. 2017). The
prevalence of DED varies depending
on the criteria used and the population
studied, but estimates range from 5 to
50% across the globe (Stapleton et al.
2017). Due to its high prevalence, DED
was in 2014 estimated to have yearly
direct and indirect costs of 55.8 billion
USD in the US alone (Yu et al. 2011).
Clinically, it is often valuable to
divide DED into two major etiological
categories: aqueous-deficient dry eye
(ADDE), which is characterized by
diminished aqueous tear production
from the lacrimal gland and evapora-
tive dry eye (EDE), categorized by
increased evaporation from the ocular
surface (Bron et al. 2017). Evaporative
dry eye (EDE) is considered the most
frequent cause of DED, although
patients often present with elements
of both types (Craig et al. 2017).
Meibomian gland dysfunction (MGD)
is likely the primary driver behind EDE
in most cases (Stapleton et al. 2017).
Despite primarily being associated with
EDE, MGD is also prevalent in
patients with Sj€ogren’s syndrome, an
important cause of ADDE (Sullivan
et al. 2018). Meibomian gland dysfunc-
tion (MGD) is characterized by
reduced meibum quality and quantity
and disruption of the meibum’s ability
to reduce ocular evaporation and sta-
bilize the tear film (Arita, Morishige,
et al. 2017; Bron et al. 2017). The tear
film’s three primary components are (1)
the mucins, produced by the conjunc-
tival goblet cells and other secretory
cells (Hodges & Dartt 2013), (2) the
aqueous tear fluid produced by the
lacrimal gland and conjunctiva, and (3)
the lipid layer consisting mainly of
meibum from the meibomian glands
(Cwiklik 2016) (Fig. 1). The meibo-
mian glands, located in the tarsal plates
of the eyelids, produce meibum in the
secretory acini and guide the meibum
through central ducts onto the ocular
surface along the eyelid margin (Knop
et al. 2011). Meibum secretion is
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regulated by blinking and the co-
ordinated contraction/relaxation of
the obicularus oculi muscle and Rio-
lan’s muscle that surrounds the orifice
of each meibomian duct.
The fluidity of themeibum is essential
for efficient draining of the glandular
structures and delivery to the ocular
surface. Whereas meibum from healthy
donors has a phase-transition tempera-
ture of around 28°C, meibum from
patients with MGD was found to
require 32°C to achieve the same fluidity
(Borchman et al. 2011). This difference
in transition temperature equates to sub-
stantially different consistencies of the
meibum at physiological temperatures,
where the eyelids often maintain a
temperature around 33°C (Butovich
et al. 2008). The difference in meibum
properties is also seen at higher temper-
atures. Meibum from subjects with
MGD showed similar viscosity at
38.5°C as meibum from healthy donors
heated to 36.0°C (Borchman 2019).
Eyelid warming treatments are, there-
fore, a key approach for MGD treat-
ment (Asbell et al. 2011; Jones et al.
2017). By raising the temperature of the
eyelids, the viscosity is reduced, and
secretion of meibum from the glandular
structure becomes easier (Fig. 2). The
treatment generally consists of deliver-
ing localized heat to the eyelids and
warming and softening the meibum
before applying pressure to express the
softened meibum.
The least expensive and most acces-
sible eyelid warming strategy consists
of applying warm, wet towels over the
closed eyelids for 5–10 min, reheating
the towel every two minutes to main-
tain heat (Geerling et al. 2011). When
heated to between 40 and 47°C and
reheated at least every two minutes, hot
towels maintain sustained therapeutic
temperatures during the entire treat-
ment period and effectively increase
eyelid temperatures (Olson et al. 2003;
Blackie et al. 2008, 2013; Murakami
et al. 2015). However, if not reheated,
hot towels quickly lose heat and drop
below adequate levels of heat for eyelid
warming (Lacroix et al. 2015; Bitton
et al. 2016). Thus, patient education
and compliance with treatment are
essential for a successful outcome. As
a response to this, commercially avail-
able options, including eyelid warming
masks (Lacroix et al. 2015), warm
moist air at-home eyelid warming
devices (Doan et al. 2014), and in-
office treatment devices (Lane et al.
2012), have been developed.
Access to effective at-home treat-
ments will likely remain key in treating
MGD. Thus, ensuring the efficacy,
safety, and ease of use of at-home
eyelid warming treatments remain
essential. This review aimed to criti-
cally evaluate the current literature on
chambered moist air eyelid warming
systems and help clinicians and patients
make informed decisions regarding this
treatment of MGD.
Methods
PubMed and EMBASE, via Ovid, were
searched on 06 June 2021, using the
search term ‘(warm OR heat OR steam
OR goggle OR spectacle OR moist air)
AND (meibomian OR MGD OR ble-
pharitis OR eyelid OR dry eye OR
DED)’. First, all articles were screened
for broad relevance to the topic, based
on title and abstract. Second review
articles, case reports, and articles with-
out English full text were excluded.
Third, duplicates in the two searches
were removed. Finally, the full text of
the resulting articles of interest was
then checked against the inclusion
criteria. The inclusion criteria were
studies evaluating the efficacy and
safety of chambered warm moist air
Fig. 1. A cross-section of the pre-corneal tear film. The three main components of the tear film are
marked. (1) The mucin produced by the conjunctival goblet cells increases water retention and tear
film viscosity. (2) The aqueous component of the mucoaqueous layer is produced by the lacrimal
gland and conjunctiva and makes up a majority of tear film volume. (3) The outer lipid layer
mainly consists of lipids produced by the meibomian glands and reduces surface tension and
ocular evaporation. Copyright, Sara Tellefsen Nøland.
Healthy meibum, 36°C Meibum in MGD, 36°C Meibum in MGD, after
warming > 38.5°C
Fig. 2. An idealized representation of the effect of successful eyelid warming. The increased
meibum viscosity at lower temperatures seen in patients with meibomian gland dysfunction
(MGD) can be mitigated through elevated eyelid temperatures. The left panel illustrates normal
meibum, and the middle panel shows the thickened meibum in a patient with MGD, at 36°C. The
right panel shows the reduced meibum viscosity observed after successful eyelid warming in the
patient with MGD. Copyright, Sara Tellefsen Nøland.
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eyelid warming systems for treating
MGD or DED. Cool-air moisture
devices (Ogawa et al. 2018) and non-
chambered heating masks (Arita, Mor-
ishige, et al. 2017; Tichenor et al. 2019;
Jeon & Park 2021) were not included.
Results
Overview of included studies
The search term ‘(warm OR heat OR
steam OR goggle OR spectacle OR
moist air) AND (meibomian ORMGD
OR blepharitis OR eyelid OR dry eye
OR DED)’ yielded 1005 results in
PubMed, stretching from March 1964
to May 2021. Based on the title and
abstract, 31 articles of interest were
further screened in full text. Using
EMBASE, 805 entries were returned,
with results ranging from 1974 to May
2021. Based on the titles and abstracts,
24 articles of interest were flagged for
further assessment. Of these, two did
not have English full text and the 22
remaining were all also retrieved in the
search using PubMed. After assessing
full texts, 18 articles were deemed
relevant and included in the review. A
depiction of the process can be seen in
Fig. 3. The included articles were pub-
lished between June 2005 and Decem-
ber 2020, describing studies conducted
across several different countries such
as the United Kingdom (Mitra et al.
2005; Spiteri et al. 2007; Purslow 2013;
Bilkhu et al. 2021), Germany (Pult
et al. 2012; Kremers et al. 2020), the
United States (Murakami et al. 2015),
China (Ren et al. 2018), New Zealand
(Turnbull et al. 2018; Wang et al.
2020), Japan (Matsumoto et al. 2006),
Singapore (Lam et al. 2014; Sim et al.
2014; Yeo et al. 2016), France (Doan
et al. 2014), Italy (Villani et al. 2015),
and Europe (Benitez Del Castillo et al.
2014)). In total, eight articles described
the results of five prospective trials
(Matsumoto et al. 2006; Benitez Del
Castillo et al. 2014; Doan et al. 2014;
Lam et al. 2014; Sim et al. 2014; Villani
et al. 2015; Yeo et al. 2016; Ambaw
et al. 2020), while 10 articles described
only single application of the device
used (Mitra et al. 2005; Spiteri et al.
2007; Pult et al. 2012; Purslow 2013;
Murakami et al. 2015; Ren et al. 2018;
Turnbull et al. 2018; Kremers et al.
2020; Wang et al. 2020; Bilkhu et al.
2021). One study described both the
effects of single application and pro-
longed use of warm moist air treatment
(Matsumoto et al. 2006). Only one
RCT assessing treatment response was
found, an assessor-masked RCT from
the Singapore National Eye Centre
with the ClinicalTrials.gov registration
number NCT 01448369, first described
by Sim et al. (2014). Table 1 presents
an overview of the studies assessing the
effects of a single application of a
chambered warm moist air eyelid
warming device while Table 2 highlight
the results of the treatment studies with
prolonged follow-up. Studies are
arranged by publication year, from
oldest to newest in both tables.
Chambered warm moist air eyelid warming
devices
The defining feature of a chambered
warm moist air eyelid warming device
is the use of steam as an indirect carrier
of moist heat within an enclosed cham-
ber surrounding the eyelids and ocular
surface. This allows the heating ele-
ments to not be in direct contact with
the skin but use the warm water vapour
to distribute heat evenly to all areas of
the ocular surface. In the included
studies, two different designs for
achieving this effect were used. One
article described an actively heated,
single-chambered device (Matsumoto
et al. 2006), while the remainder uti-
lized different goggle designs with
either active heating or latent heat
profiles (Mitra et al. 2005; Spiteri
et al. 2007; Pult et al. 2012; Purslow
2013; Benitez Del Castillo et al. 2014;
Doan et al. 2014; Lam et al. 2014; Sim
et al. 2014; Murakami et al. 2015;
Villani et al. 2015; Yeo et al. 2016;
Ren et al. 2018; Turnbull et al. 2018;
Kremers et al. 2020; Wang et al. 2020;
Bilkhu et al. 2021).
Blephasteam (Thea Pharmaceuti-
cals, Newcastle-under-Lyme, UK) was
the only named, commercially avail-
able device described in the included
articles (Pult et al. 2012; Purslow 2013;
Benitez Del Castillo et al. 2014; Doan
et al. 2014; Lam et al. 2014; Sim et al.
2014; Murakami et al. 2015; Villani
et al. 2015; Yeo et al. 2016; Turnbull
et al. 2018; Kremers et al. 2020; Bilkhu
et al. 2021), with the remaining studies
using unnamed prototypes or research
versions of devices (Mitra et al. 2005;
Matsumoto et al. 2006; Spiteri et al.
2007; Ren et al. 2018; Wang et al.
2020). Blephasteam is a latent heat
device that uses preheated thermal
elements to warm moistened ring
inserts so that the inside of the goggles
reaches 100% humidity and the desired
temperature of around 42°C. The gog-
gles must be plugged into a power
outlet for 15 minutes before applica-
tion to allow the thermal elements to
reach 50°C (Doan et al. 2014). The
goggles are then worn for 10 min,
allowing the warm water vapour to
provide even heat on the eyelids,
Initial search term:




Exclusion based on titles and abstracts:
31 articles 24 articles
PubMed:
1,005 results 805 results
Embase via Ovid:
Exclusion based on article type and 
language:
27 articles 22 articles
Fig. 3. Flow chart of the literature search conducted.
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softening the meibum (Purslow 2013).
An illustration of the Blephasteam
system is shown in Fig. 4.
Eyelid temperature after application of the
device
Four studies evaluated eyelid tempera-
ture during or after applying latent
heat goggles (Pult et al. 2012; Mur-
akami et al. 2015; Kremers et al. 2020;
Wang et al. 2020). A 10-minute appli-
cation of the standard Blephasteam
device, which is preset to warm to
50°C, warmed the outer eyelids to a
temperature between 38.1°C and
40.6°C (Pult et al. 2012; Murakami
et al. 2015; Kremers et al. 2020) and the
internal eyelid surface to 38°C (Mur-
akami et al. 2015). Using a research
prototype of Blephasteam with three
preset temperature settings, Wang et al.
found that warming the latent heat
device to 45°C, 50°C, and 55°C
increased the outer eyelid temperature
to 36.0°C, 36.3°C, and 37.3°C, respec-
tively (Wang et al. 2020).
Changes in objective and subjective
measurements
Figure 5 presents an overview of the
changes in symptom scores and the
Table 1. Studies assessing short-term effects of single application of device.
First author/
year/country
Masking Device (other study arms) Sample study arm (controls) Outcome
Mitra M 2005 GB
(Mitra et al. 2005)
Assessor-
masked
Warm moist air device
(inactivated device,
untreated controls)
Healthy subjects; n = 8, per
group
6/8 using activated and 1/8 using inactivated device
had improved symptom scores, while none of the
untreated controls improved. Those using the






No Warm moist air device MGD; n = 15
Healthy subjects; n = 20
Eyelid and cornea temperature increased with 1–2°C
to around 36°C. VAS, TBUT, and LLT improved
after treatment in subjects with MGD. Schirmer test
and OSS did not change.







Dry eye without SS; n = 12
(n = 12)
Dry eye with SS; n = 17
(n = 14)
Symptom score and LLT improved in those with the
device. Controls showed no change over time.
Pult H 2012 DE





Healthy subjects; n = 20
(crossover)
The temperature stayed above 38°C longer than non-





No Blephasteam Healthy subjects; n = 25 The ocular surface temperature increased from
around 35°C to around 38°C. Hyperemia improved.










Healthy subjects; n = 5
(crossover)
The internal lower lids were heated to 38°C, on par
with other commercial options, but less than the
Bundle method of hot towel application (40°C).
Ren Y 2018 CN
(Ren et al. 2018)




n = 22 (crossover)
VAS, TMH, TBUT, and LLT improved from
baseline with Blephasteam. No change in IOP, BRI,
or VA. Blephasteam yielded better VAS and TBUT









No MG dropout, n = 6
(n = 8, n = 7)
Mild MG dropout, n = 11
(n = 8, n = 8)
Severe MG dropout, n = 8
(n = 12, n = 13)
TBUT, LLG improved with treatment, no difference
between treatments. Greater severity of MG
dropout was tied to increased improvement. No





No Blephasteam (hot towel,
sauna)
Healthy subjects, n = 49
(n = 41, n = 9)
MGD, n = 44 (n = 31,
n = 5)
The eyelids were heated to 38°C with Blephasteam,
which was higher than towels heated to 40°C and
reheated every 2 min, and equivalent to 10 min in
an 85°C sauna.
Wang MTM 2020




Research latent heat device
at 55°C (45°C, 50°C)
Healthy subjects, n = 15
(crossover)
None of the settings heated the eyelid beyond 38°C.
LLG and TBUT improved in all groups. TBUT
improved more in the 55°C group. VA was
unchanged in all groups; no adverse events were
reported.
Bilkhu P 2020 GB
(Bilkhu et al.
2021)
No Blephasteam + liposomal
spray (no treatment)
Healthy subjects, n = 40
(crossover)
SANDE, DLP, LLT, and TMH significantly
improved with treatment. No significant change in
TBUT, evaporation rates, or blink rate with
treatment.
BRI = bulbar redness index, DLP = dynamic tear film lipid layer pattern, IOP = intraocular pressure, LLG = lipid layer grade, LLT = lipid layer
thickness, MG = meibomian gland, MGD = Meibomian gland dysfunction, OSS = ocular surface staining, SS = Sj€ogren’s syndrome, TBUT = tear
film breakup time, TMH = tear meniscus height, VA = visual acuity, VAS = visual analogue scale, VDT = video display terminal.
* Results of two-week treatment arm of study presented in Table 2.
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most commonly measured objective
parameter, tear film breakup time
(TBUT), at baseline and follow-up,
for those receiving chambered warm
moist air eyelid warming devices in the
studies presenting these values.
Results of single-application studies
In the single-application studies, ocular
comfort or symptoms were measured in
six studies (Mitra et al. 2005; Mat-
sumoto et al. 2006; Spiteri et al. 2007;
Purslow 2013; Ren et al. 2018; Bilkhu
et al. 2021). Symptoms, as measured by
the symptom assessment in dry eye
(SANDE) questionnaire (Bilkhu et al.
2021), visual analogue scale (VAS)
(Matsumoto et al. 2006; Ren et al.
2018), or not specified symptom scores
(Mitra et al. 2005; Spiteri et al. 2007),
improved in five of these studies (Mitra
et al. 2005; Matsumoto et al. 2006;
Spiteri et al. 2007; Ren et al. 2018;
Bilkhu et al. 2021). One study found no
change in VAS score in 25 healthy
subjects (Purslow 2013). The symptom
scores at baseline and follow-up are
presented in Fig. 5A, for the studies
including these values (Matsumoto
et al. 2006; Purslow 2013; Ren et al.
2018; Bilkhu et al. 2021).
Several different objective measures
were reported in the single-application
studies. Tear film breakup time (TBUT)
was found to improve in four (Mat-
sumoto et al. 2006; Ren et al. 2018;
Turnbull et al. 2018;Wang et al. 2020) of
the six studies assessing it (Matsumoto
et al. 2006; Purslow 2013; Ren et al.
2018; Turnbull et al. 2018; Wang et al.
2020; Bilkhu et al. 2021). The five studies
presenting pre- and post-treatment
TBUT values are presented in Fig. 5C
(Matsumoto et al. 2006; Purslow 2013;
Ren et al. 2018;Wang et al. 2020; Bilkhu
et al. 2021). The results did not appear to
be affected by whether TBUT was mea-
sured non-invasively (Purslow 2013;
Ren et al. 2018;Wang et al. 2020; Bilkhu
et al. 2021) or by fluorescein-based
TBUT assessment (Matsumoto et al.





Design Sample Protocol Outcome Adverse events













VAS and LLT improved in both
groups, TBUT increased in the
warm moist air device group only.
No change in OSS in either group.
ND
Benitez del Castillo
JM 2014 BE, DE,





MGD; n = 73 10 min, twice
daily, 3 w
VAS and hyperemia improved.




















No difference between groups after
1 month. A greater proportion
had symptom improvement after
3 mo of Blephasteam treatment
than after hot towels. No
difference between the groups for
the number of clogged MGs,
TBUT, meibum viscosity, or Sch.
I at any timepoint.
VA unchanged
after 3 mo.
Lam SM 2014 SG












Blephasteam, hot towel, and







Doan S 2014 FR
(Doan et al. 2014)
Blephasteam Single-group
prospective
MGD; n = 96 10 min, twice
daily, 3 w
VAS, hyperemia, and meibum
quality improved. TBUT,







Villani E 2015 IT





WC; n = 18
10 min, twice
daily, 3 w
OSDI and TBUT improved. OSS














MGD; n = 22
(n = 22,
n = 24, n = 22)
10 min, twice
daily, 3 mo
Tear film evaporation rates did not
change with Blephasteam
treatment. No difference between
groups.
ND
IOP = intraocular pressure; LLT = lipid layer thickness; MG = meibomian glands; MGD = meibomian gland dysfunction; mo = months;
ND = not described; OSDI = ocular surface disease index; PUFA = polyunsaturated fatty acids; RCT = randomized controlled trial;
SANDE = symptom assessment in dry eye; Sch. I = Schirmer test; TBUT = tear film breakup time; VA = visual acuity; VAS = visual analogue
scale; w = weeks; WC = warm compresses.
* Results of short-term efficacy and safety of single-application of device is presented in Table 1.
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2006). Lipid layer thickness (Mitra et al.
2005; Matsumoto et al. 2006; Spiteri
et al. 2007; Ren et al. 2018; Bilkhu et al.
2021), lipid layer grade (Turnbull et al.
2018; Wang et al. 2020), and lipid layer
patterns (Bilkhu et al. 2021) improved in
all single-application studies that
included these measurements. Three
studies assessed ocular surface staining
(OSS), and all three found improvement
with treatment (Matsumoto et al. 2006;
Pult et al. 2012; Purslow 2013). Visual
acuity was evaluated in four studies
(Pult et al. 2012; Purslow2013;Ren et al.
2018; Wang et al. 2020), three of which
found no change with treatment (Pur-
slow 2013; Ren et al. 2018; Wang et al.
2020), and one study found an improve-
ment from baseline (Pult et al. 2012).
Two studies found tear meniscus height
to improve (Ren et al. 2018; Bilkhu et al.
2021), while another found no change
(Turnbull et al. 2018) with treatment.
Intraocular pressure (Purslow 2013;
Ren et al. 2018) and tear evaporation
rates (Turnbull et al. 2018; Bilkhu et al.
2021) were not affected by treatment.
Results of treatment studies
Symptoms were assessed in all five
populations enrolled in studies with
follow-ups (Matsumoto et al. 2006;
Benitez Del Castillo et al. 2014; Doan
et al. 2014; Sim et al. 2014; Villani et al.
2015). One study found improvement
in the ocular surface disease index
(OSDI) in subjects not responding to
the initial warm compress treatment
after three weeks of subsequent Ble-
phasteam treatment (Villani et al.
2015). All three studies using VAS
noted improvement in symptoms after
treatment (Matsumoto et al. 2006;
Benitez Del Castillo et al. 2014; Doan
et al. 2014). One study using SANDE,
which includes a VAS score for both
symptom frequency and severity,
found that around 80% of participants
had improved both frequency and
severity of dry eye symptoms after
Blephasteam treatment (Sim et al.
2014). Mean symptom scores at base-
line and follow-up are presented in
Fig. 5B for the studies including these
values (Matsumoto et al. 2006; Benitez
Del Castillo et al. 2014; Doan et al.
2014; Villani et al. 2015).
In studies with follow-up, TBUT was
most frequently reported among the
clinical parameters (Matsumoto et al.
2006; Benitez Del Castillo et al. 2014;
Doan et al. 2014; Sim et al. 2014; Villani
et al. 2015). Two studies found improve-
ment in TBUT with treatment (Mat-
sumoto et al. 2006; Villani et al. 2015),
while the remaining three did not note
change from baseline (Benitez Del Cas-
tillo et al. 2014; Doan et al. 2014; Sim
et al. 2014). Fig. 5D shows the mean
TBUT values at baseline and follow-up
from the articles that included these
values (Matsumoto et al. 2006; Benitez
DelCastillo et al. 2014;Doan et al. 2014;
Villani et al. 2015). Ocular hyperemia
improved in both studies in which it was
assessed (Benitez Del Castillo et al.
2014; Doan et al. 2014). Lipid layer
thickness improved in the one study
measuring this (Matsumoto et al. 2006).
The meibum’s lipid composition chan-
ged with treatment, with a decrease in
lysophospholipids and an increase in
polyunsaturated fatty acid (PUFA)-
containing phospholipids (Lam et al.
2014).However,meibomian gland func-
tion scores showed inconclusive results.
Meibum quality score improved in one
study (Doan et al. 2014), but not in the
other study that assessed this (Villani
et al. 2015). Meibomian gland score did
not change in the only article that
included this measure (Sim et al. 2014).
Ocular surface staining (OSS) (Mat-
sumoto et al. 2006; Villani et al. 2015),
Schirmer test values (Benitez Del Cas-
tillo et al. 2014; Doan et al. 2014; Sim
et al. 2014), visual acuity (Benitez Del
Castillo et al. 2014;Doan et al. 2014; Sim
et al. 2014), intraocular pressure (Ben-
itez Del Castillo et al. 2014; Doan et al.
2014), tear film osmolarity (Benitez Del
Castillo et al. 2014; Doan et al. 2014),
and tear film evaporation rates (Yeo
et al. 2016) were unchanged from base-
line with treatment in all studies assess-
ing these parameters.
Results compared to other treatments in
treatment trials
Two of the populations followed over
time were compared to control groups
receiving other treatments (Matsumoto
et al. 2006; Sim et al. 2014). One was a
two-week open-label study comparing
an unnamed warm moist air device
against hot towel treatment (Mat-
sumoto et al. 2006). The other was a
three-month assessor-masked random-
ized controlled trial (RCT) comparing
Blephasteam to hot towels and Eye-
Giene (EyedetecMedical Inc., Danville,
CA, USA) treatment (Sim et al. 2014).
Although no direct statistical com-
parison between the two groups in the
first study was conducted, the warm
moist air device showed a numerically
greater improvement in VAS score
than hot towels (Matsumoto et al.
2006). The VAS scale for ocular tired-
ness changed from 34 to 82, for dryness
from 32 to 80, and for discomfort from
23 to 82, in those receiving warm moist
air treatment, where increasing score
indicated improvement. Similar num-
bers for hot towel treatment were from
46 to 60, from 36 to 61, and from 44 to
66. Only those receiving treatment with
the warm moist air device had a
significantly improved TBUT after
two weeks. Tear film breakup time
(TBUT) changed from 4.7 to 8.6 in the
treatment group and from 4.0 to 4.7 in
those receiving hot towels (Matsumoto
et al. 2006).
The only RCT assessing Ble-
phasteam treatment (NCT 01448369),
Fig. 4. The Blephasteam system is preheated for 15 min before inserting the moist rings, and the




first described by Sim et al. (Sim et al.
2014), found no significant difference
between groups in the predefined effi-
cacy outcome, which was the propor-
tion of subjects noting improvement in
frequency and severity of VAS eye
discomfort at the four-week follow-
up. However, at the additional three-
month follow-up, a significantly higher
proportion of those receiving Ble-
phasteam treatment ( 80%) had
improved scores than those receiving
hot towel treatment ( 50%) (Sim et al.
2014). In the EyeGiene group,  40%
of participants noted improved scores,
however, this group was significantly
different from the hot towel group at
baseline, possibly due to high level of
dropout. Eight of the 25 subjects
enrolled dropped out partially due to
the inability to activate the warming
units, reducing the effective sample size
below the calculated minimun sample



























































Ocular discomfort - Treatment studies
Matsumoto et al. §*
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Doan et al. *



























Ocular discomfort - Single application studies
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Tear film break-up time (TBUT) - Treatment studies
Matsumoto et al. *
Benitez et al.






















Wang et al. 45°C *
Wang et al. 50°C *





§ : Axis has been inverted, as increased VAS score indicated improvement
* : Significant change at P < 0.05 reported
Fig. 5. Change in symptom scores and tear film breakup time (TBUT) reported in the studies providing numerical values at baseline and follow-up.
(A) Change in symptoms after a single application of device (Matsumoto et al. 2006; Purslow 2013; Ren et al. 2018; Bilkhu et al. 2021). (B) Change in
symptoms after sustained use of the device (Matsumoto et al. 2006; Benitez Del Castillo et al. 2014; Doan et al. 2014; Villani et al. 2015). (C) Change
in TBUT after a single application of device (Matsumoto et al. 2006; Purslow 2013; Ren et al. 2018; Wang et al. 2020; Bilkhu et al. 2021). All three
temperatures used in Wang et al. are presented (dashed lines) (Wang et al. 2020). (D) Change in TBUT after sustained use of the device (Matsumoto
et al. 2006; Benitez Del Castillo et al. 2014; Doan et al. 2014; Villani et al. 2015).
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comparison was made between Eye-
Giene and Blephasteam. Of note, there
were significant differences between the
three groups at baseline (p = 0.0008),
relative change in symptoms scores
were not presented in the study, and
what constituted a clinically relevant
improvement in symptom score was
not described (Sim et al. 2014).
In a 32 participant subsample from
the same RCT (NCT 01448369), Lam
et al. noted no appreciable difference
between the three groups in VAS symp-
tom score, the number of blocked mei-
bomian glands, Schirmer score, TBUT,
or OSS score after three months of
treatment (Lam et al. 2014). They,
therefore, deemed the treatments equiv-
alent and subsequently pooled the
groups for tear fluid lipidome analysis
before and after routine eyelid warming
treatments. Interestingly, in the subsam-
ple, the group receiving Blephasteam
treatment showed the lowest mean
improvement in symptom score from
baseline to 12 weeks. Blephasteam
treatment yielded a mean VAS score
improvement of 0.40 for ocular discom-
fort, compared to 3.85 in those receiving
hot towel treatment and 9.70 for the
EyeGiene group (Lam et al. 2014). The
difference between those receiving Ble-
phasteam and EyeGiene was not signif-
icant (p = 0.06). When the three groups
were pooled, the authors noted a reduc-
tion in lysophospholipids and numerous
PUFA-containing diacylglyceride spe-
cies and increased expression of PUFA-
containing phospholipids (Lam et al.
2014).
Using the same inclusion criteria as in
the initial study (NCT 01448369), the
researchers later assessed LipiFlow
(Johnson & Johnson Vision, Jack-
sonville, FL, USA) treatment in 25
participants in the same clinic (NCT
01683318), first described in Zhao et al.
(Zhao et al. 2016). Tear evaporation
rates were then assessed in the groups
receiving Blephasteam, LipiFlow, hot
towel, or EyeGiene treatment from
either trial in a 2016 article (Yeo et al.
2016). The authors found no difference
in ocular evaporation rates after Ble-
phasteam treatment, or between any of
the four groups after four or twelve
weeks of treatment (Yeo et al. 2016).
Only those receiving LipiFlow, and the
pooled population of all four groups
noted a significant improvement in
evaporation rates (Yeo et al. 2016).
When adjusting for baseline differences,
there was no difference between the four
groups in the likelihood that the treat-
ment would decrease the evaporation
rate from above to below the mean of
the total population at baseline (66 W/
min) in a logistic regression model (Yeo
et al. 2016).
Lastly, 37 participants from both the
initial RCT (NCT 01448369) and the
later trial assessing LipiFlow alone
(NCT 01683318) were assessed for
changes in lipid mediators after treat-
ment (Ambaw et al. 2020). The authors
noted no appreciable differences
between the pooled group of the three
eyelid warming modalities and those
receiving LipiFlow (Ambaw et al.
2020). The authors further pooled the
results for all four groups. They
concluded that heat-based MGD ther-
apy decreased expression of pro-
inflammatory mediators produced by
lipoxygenase and oxidative stress
(Ambaw et al. 2020).
Discussion
Chambered warm moist air heat
devices have been shown safe and
effective in both short- and long-term
studies (Tables 1 and 2). Steam-based
latent heat devices increased eyelid
temperatures and improved tear film
parameters without adverse effects in
the single-application studies (Table 1).
In the treatment studies, symptoms
consistently improved with 2-weeks to
3-months of treatment, while improve-
ment in clinical signs varied between
studies (Table 2). The only RCT with
follow-up conducted found that treat-
ment with a chambered steam-based
device (Blephasteam) was more likely
to provide relief of symptoms than hot
towels after three months of treatment
(Sim et al. 2014). However, no differ-
ence between groups was noted at the
four-week follow-up (the main out-
come variable) and the magnitude of
this improvement was not shown.
The ability of an eyelid heating
device to provide sustained heat to
the eyelids without adverse effects, such
as thermal burns, is essential. Based on
the results in the single-application
studies, Blephasteam appeared to effec-
tively heat the eyelids to therapeutic
levels (38–40°C) (Pult et al. 2012;
Murakami et al. 2015; Kremers et al.
2020) while remaining comfortable to
use (Spiteri et al. 2007; Ren et al. 2018;
Bilkhu et al. 2021). In a recent study of
the ex-vivo thermochemical properties
of meibum, 41.5°C was found to likely
be the optimal temperature for soften-
ing the meibum from patients with
MGD (Borchman 2019). However,
already at 38.5°C, the fluidity of the
meibum was shown to be similar to
that of healthy donors at baseline
(36°C) (Borchman 2019). This is sup-
ported by the findings in the single-
application studies that noted improve-
ment in lipid layer thickness (Mitra
et al. 2005; Matsumoto et al. 2006; Ren
et al. 2018; Bilkhu et al. 2021), indicat-
ing an increased expression of meibum
after application.
The benefits of applying wet or dry
heat have been debated, with studies
reaching differing conclusions (Arita
et al. 2015; Murakami et al. 2015). The
evaporation of remaining moisture
after wet heat treatment could acceler-
ate cooling after cessation of applica-
tion (Arita et al. 2015). Kremers et al.
found external eyelid temperatures to
fall rapidly after Blephasteam treat-
ment, from around 38°C immediately
after application to roughly baseline
temperature (35°C) only two minutes
later (Kremers et al. 2020). The fall in
temperature after applying hot towels
replaced at least every two minutes or
after having a sauna was more gradual.
Based on these findings, it is plausible
that the eyelids could lose heat more
rapidly after warm moist air eyelid
warming treatments than after applica-
tion dry heat, affecting ensuring eyelid
hygiene routines if these are to be
performed. However, more research is
needed to explore differences between
modalities and possible clinical impli-
cations.
The direct effect of the initial tem-
perature of latent heat devices has been
assessed (Wang et al. 2020). A research
prototype of Blephasteam improved
TBUT in participants with minimal-
to-mild dry eye symptoms significantly
more when the device was preheated to
55°C than 50°C or 45°C, without
observed adverse effects. The commer-
cially available Blephasteam device
currently only has a single heat-
setting, which is 50°C (Wang et al.
2020). Increasing this to 55°C could
thus potentially benefit patients using
this device. However, further studies
into the safety and efficacy of increased
baseline temperature on patient with




Several benefits of steam treatment
were noted in both the single-
application and treatment studies when
assessing those receiving Blephasteam
or other chambered steam-based eyelid
warming devices. When assessing par-
ticipants with MGD, symptom scores
and TBUT improved in all single-
application studies that assessed these
measures (Matsumoto et al. 2006; Spi-
teri et al. 2007; Ren et al. 2018;
Turnbull et al. 2018). Similarly, symp-
toms significantly improved with steam
treatment in all prospective studies
reporting this (Matsumoto et al. 2006;
Benitez Del Castillo et al. 2014; Doan
et al. 2014; Villani et al. 2015)
(Fig. 5B). Additionally, when assessed
alongside a control group receiving hot
towel treatment, only Blephasteam was
found to improve TBUT significantly
(Matsumoto et al. 2006). However,
only one RCT with follow-up has been
conducted (Sim et al. 2014). Further-
more, a possible benefit with the Ble-
phasteam device not found with other
eyemasks is the ability to blink freely,
promoting the natural excretion of
meibum, and the option to read or
watch videos during treatment (Doan
et al. 2014).
The only prospective RCT con-
ducted to date had several method-
ological shortcomings that weaken the
conclusions drawn. There was a signif-
icant difference in symptom severity
scores across the three groups at base-
line (p = 0.0008), with lower VAS
scores in the EyeGiene group (23.6)
than the groups receiving hot towels
(52.8) and Blephasteam (41.4) (Sim
et al. 2014). The main outcome mea-
sure was the proportion of participants
noting improvement in severity and
frequency of symptom on a VAS scale
in each group after four weeks, the
predefined study duration (NCT
01448369). However, the authors did
not define what qualified as a clinically
relevant improvement or report the
mean change in symptom score per
group (Sim et al. 2014). This is impor-
tant to note, as the researchers found
no difference in mean change in symp-
tom score between the groups in an
article describing a subsample from the
same study population (Lam et al.
2014). In fact, in the subsample of 32
participants, the group receiving Ble-
phasteam seemed to have the lowest
mean symptom improvement of the
three groups, on the borderline of
being significantly different from the
EyeGiene group (p = 0.06). The sup-
plemental material further described
that in the Blephasteam group, only
1/10 noted an improvement of more
than five units on the VAS scale for
ocular discomfort, and 2/10 on the
summed global score. Similar numbers
for the hot towel group were 3/10 and
3/10 and for the EyeGiene group 7/12
and 6/12 respectively (Lam et al. 2014).
To assess what constitutes a clini-
cally relevant change, the ‘minimal
clinically important difference’ is a
valuable tool (Jaeschke et al. 1989).
This measure describes the smallest
change in a relevant score that would,
barring adverse side-effects, warrant a
change in a patient’s clinical treatment.
There is no consensus-based minimal
clinically important difference for
SANDE or other VAS scores for dry
eye discomfort. For the OSDI score,
which also stretches from 0 to 100, the
minimal clinically relevant difference
has been reported to range from 7.0 to
9.9 units across all OSDI categories
(Miller et al. 2010). When assessing the
initial repeatability and validity of the
SANDE questionnaire, 50% of
answers on the VAS scale varied more
than 10 units when the same partici-
pant was reassessed by mail a few days
after being assessed in the clinic
(Schaumberg et al. 2007). Additionally,
in general, pain management literature,
the minimal clinically relevant differ-
ence in VAS pain scales from 0 to 100
ranged from 8 to 40 units for acute
pain (Olsen et al. 2017) with a median
of 23 units across 50 studies assessing
chronic pain (Olsen et al. 2018). Based
on this, changes smaller than 10 units
on a VAS scale from 0 to 100 for ocular
discomfort are unlikely to constitute
clinically relevant improvement.
Overall, the results of both the
single-application and treatment stud-
ies indicate that chambered warm
moist air eyelid warming devices
appear to be safe and effective at
increasing eyelid temperature and
improving dry eye signs and symptoms.
However, due to shortcomings of the
only prospective RCT conducted and
the absence of statistical comparison
between Blephasteam and EyeGiene
(Sim et al. 2014), it is still unclear if
chambered warm moist air eyelid
warming devices provide additional
benefits over other eyelid warming
treatments.
A well-conducted RCT directly com-
paring chambered warm moist air eye-
lid warming to other at-home
treatments, such as eye masks and hot
towels, is needed to determine if steam-
based heating provides any additional
benefits. As dropout proved to be a
challenge in the only RCT conducted,
future studies should consider this by
enrolling a larger initial sample size.
Additionally, assessment of compliance
with different treatments would pro-
vide useful information, as high pref-
erential dropout rates could be
indicative of generally low compliance
in one or more groups. Furthermore,
direct statistical comparison across all
included treatment modalities should
be conducted to avoid potential bias.
Additionally, no study with a follow-
up period longer than 12 weeks has
been undertaken, thus, the long-term
effects of prolonged habitual cham-
bered warm moist air eyelid warming
on the ocular environment are
unknown. As MGD is a chronic con-
dition and life-long treatment is often
required, a study assessing benefits and
adverse effects and compliance of pro-
longed steam-based treatment (at least
12–24 months) would provide useful
information. Moreover, there is limited
information about patient preferences
for different eyelid warming modalities.
Future comparative studies should
assess patient preferences regarding
effectiveness, costs, and ease of use of
chambered warm moist air treatment
and other modalities. Furthermore, the
long-term effects of increasing the tem-
perature of such devices by several
degrees, both in terms of their safety
and efficacy, should be explored in
future studies.
A limitation of this review is the
exclusion of any article without avail-
able English full text. However, this
was a necessary step in ensuring a
thorough assessment of all included
studies, and critical evaluation of the
findings. Additionally, due to the lack
of prospective controlled trials, it was
not possible to conduct a meta-analysis
of the data, which could have provided
useful insights.
Conclusion
Chambered warm moist air eyelid
warming devices, such as Blephasteam,
provide sustained heat and improve
signs and symptoms of DED. The
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approach appears to be a safe and an
effective form of treatment for MGD.
However, it is not clear if steam-based
eyelid warming provides any benefits
over other, more accessible treatments,
and there is a need for larger, well-
conducted RCTs directly comparing
chambered warm moist air treatments
to eyelid warming using hot towels and
commercially available eyelid warming
masks.
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